-
2024-516253-49-00
4
advanced/metastatic HER2-positive breast carcinoma
-
2023-504135-40-00
5
Classical Homocystinuria
-
2023-508563-73-00
10
Prevention of Group B streptococcus infection
-
2023-508658-24-00
4
type B3 thymoma and thymic carcinoma
-
2023-509176-42-00
11
Obesity and T2D
-
2024-510717-15-00
9
Acute myeloid leukemia
-
2024-511168-10-00
4
Primary or Secondary Progressive Multiple Sclerosis
-
2024-512195-35-00
5
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
-
2024-513724-42-00
10
Medulloblastoma
-
2024-513740-28-00
5
Respiratory Syncytial Virus and Human Metapneumovirus
-
2024-515074-26-00
1
liver cirrhosis
-
2024-515202-84-00
10
Anemia in subjects with sickle cell disease (SCD)
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517339-30-00
7
Advanced Solid Tumors
-
2024-518026-32-00
5
Invasive Breast Cancer
-
2024-518349-85-01
5
small bowel adenocarcinoma
-
2024-518508-31-00
6
High risk atrial fibrillation patients with previous intracranial
hemo
-
2024-518692-56-00
6
Pregnant
-
2024-518821-13-00
4
Non-cystic Fibrosis Bronchiectasis
-
2024-518822-33-01
6
Cerebral Palsy
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2024-519935-41-00
5
Short predicted height